Some are disappointed. I am pretty happy. Here are numbers I have on other launches. Does anyone else have any to add?
1st full week of Belviq 1,829 (weight)
2nd full week of Vascepa 252 (triglycerides)
2nd full week of Qsymia 583 (weight)
2nd full week of Victoza 411 (Diabetes)
2nd full week of Bydureon 343 (Diabetes)
I know it looks like it's doing well compared to those other launches, but keep in mind that some blockbuster drugs saw over 10,000 prescriptions during their first week of sales. With that said, I hope we'll see continued growth.
Today I sold 40K of DAN that was a buy at $0.28. Using the DAN sale for a second ARNA cash account. AF and Crashmer can holler and tell all that Arna is not a buy, but I know a great buy when I see one. By the way, Crashmer never gave a buy recommendation for DAN at under a dollar. I guess his dart board doesn't always work.
A lot of noise (and stock exploitation) about sales projections..... for perspective, the sales for Q took months to hit 4,000 per week (yes, of course they had restrictions and go it alone issues), and every major holiday week so far, there was a noticable sales lag ..... but consider this simple example of what happens if 20% week over week is possible (just starting with 1000 as a round number baseline)....
Shows that 20% is not bad at all if it is a sustained trend.... next week has holiday week numbers, then the following week we'll see a better trend indicator (imo, do your own DD, make your own decisions).